expression of PKM2 target gene and induces glucose uptake and lactate production ( Fig. l and m) . Finally, we demonstrated that IQBP overcomes docetaxel (DTX)-induced chemoresistance through inhibiting Warburg effect in vivo ( Fig. n and o) .
INTRODUCTION AND OBJECTIVES:
Early studies have found that tumor-associated macrophages (TAMs) promote cancer progression. We previously reported that TAMs promote prostate cancer metastasis via activation of the CCL2-CCR2 axis. Recently, it was reported that the CCR4 (receptor of CCL17 and CCL22) expression level in breast cancer was associated with lung metastasis. However, the role of CCR4 and the relationship between CCR2 and CCR4 in prostate cancer is unclear. The aim of this study was to elucidate the role of CCR4 and the relationship between CCL2-CCR2 axis and CCL17/ CCL22-CCR4 axis in prostate cancer progression.
METHODS: Human prostate cancer cell line cells and monocyte-lineage cells were used. Transwell migration and invasion assays co-cultured with or without macrophages were performed. Chemokines and their receptors in prostate cancer cells were measured. CCR2 and CCR4 in prostate cancer tissue were immunohistochemically analyzed. RESULTS: Co-culture of macrophages and prostate cancer cells increased prostate cancer cell migration and invasion and induced secretion of CCL2. CCL2 promoted prostate cancer cell migration in an autocrine manner and induced CCR2, CCR4 expressions, and CCL22 secretion of prostate cancer cells. RT-PCR, western blotting, and immunocytochemical staining revealed both CCR2 and CCR4 expressions in prostate cancer cells. CCL22 also promoted prostate cancer cell migration. Blockade of the CCL2-CCR2 or CCL17/22-CCR4 axis with receptor antagonist inhibited the migration of prostate cancer cells. The CCL2-CCR2 and CCL22-CCR4 axes increased phosphorylation of Akt and Erk1/2. Although both CCR2 and CCR4 antagonists could inhibit phosphorylation of Akt and Erk1/2, the CCR4 antagonist, compared with the CCR2 antagonist, strongly inhibited phosphorylation of Akt. CCR4 may have contributed more to prostate cancer cell migration than did CCR2. CCR4 and CCR2 were increased in prostate cancer tissues by IHC staining. Interestingly, the staining intensities of CCR2 and CCR4 in each specimen were significantly correlated. Moreover, the staining intensity of CCR4 was correlated with the progression of TNM stage.
CONCLUSIONS: This is the first study to show that CCR4 was expressed in prostate cancer cell lines and human prostate cancer tissues and that the CCL22-CCR4 axis contributed to prostate cancer migration and invasion. Targeting of the CCL22-CCR4 axis, which is activated by TAMs, may be a novel therapeutic target and a potential biomarker for prostate cancer.
INTRODUCTION AND OBJECTIVES: Novel strategies for candidate biomarker discovery in prostate cancer (PC) are needed to address the lack of specificity of prostate specific antigen (PSA) in PC screening and diagnosis. Urine is a very attractive biological fluid for prostate cancer biomarker discovery and measurement, since it is easy to obtain, non-invasive and may reflect biochemical processes within the prostate. Our aim is to search for proteins in the urine of patients with diagnosis of PC using isobaric labeling combined with high sensitive mass spectrometry-based proteomics.
METHODS: In this study we performed isobaric labeling combined with high sensitive and accurate mass spectrometry-based proteomics to identify proteins that are differentially expressed in the urine of men with PC comparing with those with benign prostate hyperplasia (BPH).
RESULTS: In total, 725 proteins were identified; amongst them 51 and 73 proteins were up and down regulated respectively in patients with PC. Two peptides from MMP-9 and Ly-6/neurotoxin-like were identified significantly up-regulated in PC and were further validated using a complementary targeted proteomic approach. Furthermore, we also quantified the expression of MMP9 in a set of 10 control and 17 prostate cancer urines, using ELISA, demonstrating that the expression of MMP9 is statistically higher in the urines from prostate cancer patients compared to controls (T-test, p<0.05). The activity of metalloproteinase was measured using zymography but no correlation between expression and activity in the urine samples from BPH and PC was observed. METHODS: Annotated TMAs of patients who underwent radical prostatectomy (RP) for PCa were stained for Meis and scored by a single genitourinary pathologist. NPV was calculated for the ability of Meis positivity (+Meis) to predict clinical metastasis, defined as radiographic or pathologic evidence of metastasis. RNA-seq of 26 tumors, and 90 metastases were obtained from publically available data. The 26 tumors were stratified by Meis expression, and pair-wise analysis to the metastases identified genes in low Meis tumors associated with metastatic progression.
RESULTS: A total of 99 patients underwent RP for PCa. There was no difference in age, race, stage, or Gleason grade among +Meis and Meis negative (-Meis) patients. 23% (n¼ 23) of patients had a +Meis score. 10% (n¼ 10) of patients demonstrated evidence of clinical metastasis. Of the 76 -Meis patients, 13% (n¼ 10) developed clinical metastasis; 0 +Meis patients developed metastasis (NPV¼ 100%). RNA-Seq of Meis low tumors had an expression profile closest to metastatic lesions compared to Meis high tumors. Pair wise analysis of tumors compared to metastases identified 1082 differentially expressed genes (DEG) in Meis low tumors associated with metastatic progression.
CONCLUSIONS: +Meis negatively predicted 100% of clinical metastasis in post-RP PCa, supporting its prognostic role in PCa. RNA-Seq identified 1082 DEG associated with Meis low tumors and metastatic progression. Further analysis of these genes can potentially identify novel approaches toward preventing and treating metastatic PCa. Recently, it has been shown that upregulation of the opiorphin gene (encoding an endogenous neutral endopeptidase inhibitor involved in the hypoxic response) is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery. In the present studies we determined whether opiorphin is also upregulated in PrCa, and if it plays a role in the hypoxic response in PrCa cells.
METHODS: We searched the Gene Expression Omnibus (GEO), a public functional genomics data repository administered by the NCBI, for evidence of opiorphin gene (ProL1) expression. Quantitative-(qt)-RT-PCR was used to compare expression of ProL1 in 41 PrCa tissues and 7 control, non-cancerous prostate tissue present on a commercially available tissue array. Two PrCa cell lines (LnCaP, androgen dependent and PC-3, androgen independent) were exposed to hypoxia for various lengths of time (1-24 hours, RNA isolated and expression of opiorphin and other genes involved in the hypoxic response determined by qt-RT-PCR or microarray analysis.
RESULTS: A search of GEO data demonstrated that the gene encoding opiorphin (ProL1) was significantly upregulated in PrCa. We confirmed a significant upregulation, with a trend for greater upregulation with PrCa stage, on an RNA PrCa tissue array. We found hypoxia resulted in an early (2h) 2-fold upregulation of ProL1 in LnCaP cells. In
